1. Current and future issues in the manufacturing and development of monoclonal antibodies;Kozlowski;Adv. Drug Deliv. Rev.,2006
2. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2004) ICH Harmonized Tripartite Guideline Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process (CPMP/ICH/5721/03), ICH, Geneva
3. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (1999) ICH Harmonized Tripartite Guideline Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (CPMP/ICH/365/96), ICH, Geneva
4. The European Agency for the Evaluation of Medicinal Products (2007) Guideline on Comparability of Biotechnology-derived Medicinal Products After a Change in the Manufacturing Process: Non-clinical and Clinical Issues (EMEA/CHMP/BMWP/101695/2006), EMA, London
5. US Department of Health and Human Services Food and Drug Administration (2003). Guidance for Industry (draft): Comparability Protocols – Protein Drug Products and Biological Products – Chemistry, Manufacturing and Controls Information, FDA, Rockville, MD